EDGEWISE THERAPEUTICS INC

Edgewise Therapeutics’ CMO buys 65,000 stock‑options, signaling strong confidence amid a 392% social‑media buzz surge and a near‑future price rally.

Edgewise’s insider buys signal bullish confidence—CFO, CEO, and key execs stake big options, hinting at upside if upcoming trials succeed.

Edgewise Therapeutics insider buying shows CEO Russell Alan J’s confidence in new therapies—could signal future gains amid high volatility.

Edgewise insider buying signals confidence in Phase 2 successes and Phase 3 launch, hinting at future upside amid high‑growth, pre‑profit risks.

Edgewise Therapeutics insider Thompson Peter A. receives a $0.00 options grant amid Phase‑3 launch momentum, signaling management confidence and long‑term growth potential.

Edgewise Therapeutics’ CMO’s sudden sale and bulk buy reveal a mix of portfolio rebalancing and bullish confidence, hinting at upcoming biotech breakthroughs.

Edgewise Therapeutics’ CMO buys 28,662 shares at $7.08, showing confidence in its musculoskeletal drug pipeline—watch insider moves and clinical data for signals.

Edgewise Therapeutics insider activity: CMO Joanne Donovan’s buy‑low and sell‑high trades reveal potential undervaluation and liquidity strategy.